Table 1 Patient baseline demographics and clinical characteristics at enrollment (n = 30)
Patient Characteristics | Parameters | Overall n (%) | 1 month PCS within 2SD of NBS (n = 18) | 1 month PCS > 2SD below NBS (n = 12) | p-value | |
|---|---|---|---|---|---|---|
Age | Median (range) | 62 (35–82) | 60.8 | 61.3 | 0.46 | |
Gender | Male | 23 (77%) | 13 | 10 | 0.31 | |
Female | 7 (23%) | 5 | 2 | |||
Ethnicity | White | 24 (80%) | 14 | 10 | 0.37 | |
Black | 4 (13%) | 3 | 1 | |||
Other | 2 (7%) | 1 | 1 | |||
HCC Etiology | HCV | 16 (53%) | 10 | 6 | 0.42 | |
HBV | 2 (7%) | 1 | 1 | |||
ALD | 5 (17%) | 3 | 2 | |||
Other causes of cirrhosis | 7 (23%) | 4 | 3 | |||
Non-Liver Comorbidities (e.g. Hypertension, Diabetes) | Present | 22 (73%) | 14 | 8 | 0.25 | |
Absent | 8 (27%) | 4 | 4 | |||
Portal Hypertension | Present | 20 (67%) | 11 | 9 | 0.43 | |
Absent | 10 (33%) | 7 | 3 | |||
Hepatic Encephalopathy | Present | 3 (10%) | 1 | 2 | 0.33 | |
Absent | 27 (90%) | 17 | 10 | |||
Child-Pugh Class | A | 20 (67%) | 11 | 9 | 0.19 | |
B | 10 (33%) | 7 | 3 | |||
C | 0 (0%) | 0 | 0 | |||
ECOG Performance Status | 0 | 13 (43%) | 9 | 4 | 0.17 | |
1 | 17 (57%) | 9 | 8 | |||
Tumor Morphology | Tumor Locations | Unilobar | 19 (63%) | 12 | 7 | 0.82 |
Bilobar | 11 (37%) | 6 | 5 | |||
Number of Nodules | Solitary | 11 (37%) | 7 | 4 | 0.23 | |
Multiple | 19 (63%) | 11 | 8 | |||
Mean largest tumor size (cm) | 9.2 (4.9–19) | 9.7 | 9.1 | 0.04 | ||
Mean largest tumor volume (cm3) | 588 (145–1136) | 580 | 602 | 0.42 | ||
Tumor Burden | <50% | 20 (67%) | 11 | 9 | 0.20 | |
50%–75% | 10 (33%) | 7 | 3 | |||
>75% | 0 (0%) | 0 | 0 | |||
Portal Vein Thrombosis (PVT) | Presence | Present | 30 (100%) | 18 | 12 | 0.26 |
Absent | 0 (0%) | 0 | 0 | |||
Location | Main PV | 6 (20%) | 4 | 2 | 0.63 | |
Branch PV | 24 (80%) | 14 | 10 | |||
Degree of Occlusion | Occlusive | 23 (77%) | 13 | 10 | 0.30 | |
Non-Occlusive | 7 (23%) | 5 | 2 | |||
Laboratory Data | Mean Serum AFP (ng/dl) | 715 (3.3 to >2400) | 703 | 801 | 0.36 | |
Previous Treatment | No | 10 (33%) | 7 | 3 | 0.22 | |
Yes | 20 (67%) | 11 | 9 | |||
Type of Previous Treatmenta | cTACE/DEB-TACE | 14 (47%) | 10 | 4 | 0.19 | |
RFA | 0 (0%) | 0 | 0 | |||
Liver Resection | 0 (0%) | 0 | 0 | |||
Sorafeniba | 6 (20%) | 4 | 2 | |||
Lung Shunt Fraction (LSF) | Mean (%) | 11.0 (5.1–19.8) | 11.3 | 10.8 | 0.52 | |